Skip to content
TriangleGet started
← Full study record

NCT00154102 · MORE INFO

Limitations, agreements, and source contact

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) · Source last updated 2017-01-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
A non-specific outcome measure 'Safety' was deleted from the entry in error. A replacement outcome was created. The outcome refers to adverse events.
point Of Contact
email
monika.foerster@merck.de
organization
Merck Serono
phone
+496151729517
title
Monika Foerster/Clinical Trial Leader
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
A non-specific outcome measure 'Safety' was deleted from the entry in error. A replacement outcome was created. The outcome refers to adverse events.
point Of Contact
email
monika.foerster@merck.de
organization
Merck Serono
phone
+496151729517
title
Monika Foerster/Clinical Trial Leader

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice